Table 1.

Baseline characteristics of women in the PPSDiab study, at the time of the baseline visit (3–16 months after the index pregnancy), by GDM status stratification (total n=196)

Group	Post-GDM	Control	P value
No. of subjects (%)	129	67
Clinical characteristics
Insulin therapy during pregnancy (%)	72 (36.7)	0
Glucose metabolism (%)
NGT	85 (65.9)	63 (94.0)	<0.001
IFG	20 (15.5)	2 (3.0)	<0.01
IGT	18 (14.0)	2 (3.0)	<0.05
IFG+IGT	6 (4.7)	0	<0.096
T2DM	0	0
Age (years) (mean±SD)	35.5 (± 4.0)	35.4 (± 4.2)	0.968
BMI (kg/m²) (median (Q1–Q3))	23.6 (21.4–27.8)	22.1 (20.8–25.2)	0.009
Waist circumference (cm) (median (Q1–Q3))	79.0 (74.0–86.0)	75.0 (71.0–81.5)	0.002
Systolic blood pressure (mm Hg) (median (Q1–Q3))	119.0 (111.0–125.0)	111.0 (104.0–119.5)	<0.001
Diastolic blood pressure (mm Hg) (median (Q1–Q3))	74.0 (69.0–79.0)	69.0 (64.0–77.0)	<0.001

Bold values are statistically significant

BMI, body mass index; GDM, gestational diabetes mellitus; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; NGT, normal glucose tolerance; PPSDiab, Prediction, Prevention, and Subclassification of Type 2 Diabetes; T2DM, type 2 diabetes mellitus.